NCT04082832View on ClinicalTrials.gov

CuATSM Compared With Placebo for Treatment of ALS/MND

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2019

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2020

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Cu(II)ATSM

oral suspension

DRUG

Placebos

oral suspension

Trial Locations (1)

Unknown

RECRUITING

Macquarie University, Macquarie

Sponsors
All Listed Sponsors
lead

Collaborative Medicinal Development Pty Limited

INDUSTRY

NCT04082832 - CuATSM Compared With Placebo for Treatment of ALS/MND | Biotech Hunter | Biotech Hunter